JEFFREY REDIGER: Open Payments
NPI 1871525675 · SANTA ROSA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$369 in 18 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $369
Food & beverage: $369
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Lundbeck LLC | 3 | $55 |
| Alkermes, Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ABBVIE INC. | 1 | $16 |
Products named: REXULTI, CAPLYTA, ARISTADA, UZEDY, INGREZZA, ABILIFY MAINTENA, COBENFY, VRAYLAR.
Industry payments across CA — which companies pay providers there.
